Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant 5-fluorouracil after thermal ablation for HPV-positive women with HIV in Kenya
PACTR202601771235525Phase 2Not yet recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in human papillomavirus infection comparing Adjuvant 5-fluorouracil following thermal ablation with Placebo cream following thermal ablation (2 arms). Primary endpoint: High-risk HPV clearance at 24 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
fluorouracil
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on PACTR202601771235525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202601771235525.